Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy.
Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy.
复制标题
单独使用依泽替米贝可降低接受联合抗逆转录病毒治疗的 HIV 感染患者的低密度脂蛋白胆固醇。
DOI：
10.1086/592116
复制
发表时间：
2008
期刊：
影响因子：
--
通讯作者：
Hsue,Priscilla
中科院分区：
文献类型：
--
作者：
Wohl,DavidA;Waters,David;SimpsonJr,RossJ;Richard,Susan;Schnell,Amanda;Napravnik,Sonia;Keys,Jessica;EronJr,JJoseph;Hsue,Priscilla
In this crossover study of ezetimibe monotherapy in 48 antiretroviral-treated patients with human immunodeficiency virus infection, the mean changes in low-density lipoprotein cholesterol were −5.3% (−11 mg/dL) and +5.5% (+4 mg/dL) with ezetimibe treatment and placebo, respectively (P=.04). Ezetimibe was safe and effective in reducing low-density lipoprotein cholesterol and is an option for patients who cannot tolerate treatment with a statin.
